Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06273891 · ClinicalTrials.gov registry record · Phase 3
Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes
A Phase 3 study of Premature Rupture of Membrane, sponsored by Inova Health Care Services.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
- 2
- Study locations
NCT06273891: Recruiting Phase 3 study of Premature Rupture of Membrane, sponsored by Inova Health Care Services.
NCT06273891 is a Phase 3 study of Premature Rupture of Membrane that is actively recruiting participants, run by Inova Health Care Services. The registered enrollment target is 140 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06273891, a Phase 3 study of Premature Rupture of Membrane, is actively recruiting participants, sponsored by Inova Health Care Services.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this study is to help identify the best antibiotic treatment for pregnant people when their water breaks prematurely (a condition abbreviated as PPROM). Current practice is to attempt to maintain the pregnancy until at least 34 weeks gestational age, when the risks of prematurity to the baby are lessened. Research shows that antibiotics help the pregnancy last longer, but there have been limited studies about which combination works best. Currently, both azithromycin and erythromycin are accepted antibiotic treatments, in addition to ampicillin and amoxicillin. Participants diagnosed with PPROM will be randomized to receive ampicillin and amoxicillin plus either azithromycin or erythromycin, in addition to the care they would normally receive. Studying these two drugs will help decide the best care for future patients with PPROM.
Primary Outcome
Time from PPROM to delivery between the two treatments
Conditions Studied
Interventions
- DRUG Azithromycin
- DRUG Erythromycin
Study Locations (2)
Virginia
- Inova Fairfax Medical Campus - Falls Church
- Eastern Viriginia Medical School - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2024-03-08 |
| Est. Completion | 2026-10-01 |
| Phase | Phase 3 |
What NCT06273891 shows while recruiting
NCT06273891 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Premature Rupture of Membrane appearing as the primary indexed condition, and to 2 interventions - of which Azithromycin is the first listed.
NCT06273891 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06273891 about?
NCT06273891 is a clinical study titled "Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes". The goal of this study is to help identify the best antibiotic treatment for pregnant people when their water breaks prematurely (a condition abbreviated as PPROM). Current practice is to attempt to maintain the pregnancy until at least 34 weeks gestational age, when the risks of prematurity to the ...
What is the current status of trial NCT06273891?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2024-03-08. Estimated completion is 2026-10-01.
What conditions does trial NCT06273891 study?
This clinical trial studies the following conditions: Premature Rupture of Membrane.
What interventions are being tested in trial NCT06273891?
The interventions under investigation include: Azithromycin (DRUG), Erythromycin (DRUG).
Who is sponsoring clinical trial NCT06273891?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06273891 being conducted?
This trial has 2 study locations across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Premature Rupture of Membrane
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06273891's enrollment target sits among peer trials
140 1566th of 2000 higher than 424 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI